Topic: neurodegenerative diseases
Based on phase 2 data, a Georgetown University team showed that Tasigna reduces toxic protein clumps and restores dopamine metabolism in Parkinson's.
IBM researchers have identified four proteins in blood that can predict the buildup of amyloid-beta, a marker of Alzheimer's, with high accuracy.
Researchers at the University of Pittsburgh have figured out a way to harness the harmful protein TDP-43 so it can't form toxic clumps in the brain.
The agreement tasks AbCellera with generating panels of antibodies for up to eight targets picked by Denali.
Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
Neurogene will push forward multiple gene therapy programs, invest in new technology and build its own viral vector manufacturing site for therapies.
Immuno-neurology developer Alector priced out a $176 million listing, while mitochondria-focused Stealth BioTherapeutics aims to raise $81 million.
A connection between TDP-43, which has been implicated in ALS, and another gene could yield new approaches to treating the disease.
The partners will work to develop adeno-associated virus vectors capable of crossing the blood-brain barrier.
A discovery of a mechanism that clears the toxic brain protein tau could lead to new ideas for treating Alzheimer's.